Cubist Pharmaceuticals, Inc. Announces Fourth Quarter 2006 U.S. Net Product Revenues Of $56.2 Million And Full Year 2006 U.S. Net Product Revenues Of $189.5 Million

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported U.S. net product revenues of $56.2 million (unaudited) for the fourth quarter of 2006 for its antibiotic product CUBICIN® (daptomycin for injection). This result represents an increase of 54%, or $19.6 million, from fourth quarter 2005 U.S. net product revenues. Full year 2006 U.S. net product revenues were $189.5 million (unaudited).